Corporation
Pfizer Canada ULC
- Meetings this Parliament
- 35
- With MPs
- 12
- Since Nov 2021
- 114
- Active registrations
- 1
Most recent reported meeting: Aug 6, 2026.
Lobbying by Pfizer Canada ULC: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Jul 13, 2026
Filed by An Van Gerven, President
Lobbyists
- An Van Gerven · President
-
Steven Hogue · Director, Global Policy and Public Affairs (Canada)
Former public office holder
Formerly Deputy Director of Communications, Communications, Office of the Prime Minister of Canada (2002–2003)
Formerly Special Assistant (Quebec Issues), Operations, Office of the Prime Minister of Canada (2001–2002)
Formerly Special Assistant (Quebec and Atlantic Issues), Minister's Office, Department of Fisheries & Oceans (1999–2001)
Formerly Special Assistant (Quebec and Atlantic Issues), Minister's Office, Canada Customs and Revenue Agency (1998–1999)
Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canada Border Services Agency (CBSA), Canada Economic Development for Quebec Regions, Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (22)Hide details
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB).
- Free trade agreements as they relate to the biopharmaceutical industry.
- Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
- Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.
- Advocacy related to the new Buy Canada policy and the implications of including goods and services related to healthcare delivery, medical treatment, in particular drugs, vaccines and biologicals.
- Advocacy as it relates to the Government of Canada potential responses to the US Administration Most Favored Nation drug pricing policy
- Monitoring and engaging on the Government’s national strategy for rare diseases; the Canadian Drug Agency; and the implementation of C64, An Act to Implement pharmacare.
- Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related new guidelines.
- Advocacy on the Regulations Amending the Patent Rules and Certain Regulations Made Under the Patent Act which were published for consultation in Canada Gazette Part I (CGI) on May 18, 2024.1 Share concerns with Canada’s implementation of a patent term adjustment (PTA) system that is not compliant with its trade obligations, as it does not provide a meaningful remedy to patentees who are impacted by unreasonable patent office delays.
- Advocacy related to the federal government consultation on the review of the Canada US Mexico Trade Agreement
- Advocacy on the role of the Health Emergency Readiness Canada (HERC) Agency
- Advocacy with respect to Canada's proposed Countermeasures in Response to United States Tariffs on Canadian goods
- The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
- Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Drug Agency as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance.
- Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy
- Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages
- Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
- Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.
- Discussions on the procurement of a COVID19 vaccine and therapy
- Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver and the World Health Organization pandemic treaty proposal
- Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
- Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
Registration 960525-15283-47. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Najah Sampson (55), An Van Gerven (36), Cole C. Pinnow (23).
-
Reported by Najah Sampson · In-house (corporation)
- Stephen Ellis · Member of Parliament, House of Commons
HealthIndustryInternational Trade
-
Reported by Najah Sampson · In-house (corporation)
- Randy Hoback · Member of Parliament
HealthIndustryInternational Trade
-
Reported by Najah Sampson · In-house (corporation)
- Jean-Sebastien Bock · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
- Eshan Naik · Director of Policy, Health Canada (HC)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Christopher Johnstone · Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Jennifer Miller · Assistant Secretary, Privy Council Office (PCO)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Jennifer Miller · Assistant Secretary, Privy Council Office (PCO)
- Jeff Waring · Associate Assistant Secretary, Privy Council Office (PCO)
- Alexis Conrad · Assistant Secretary to the Cabinet, Privy Council Office (PCO)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Marie-Françoise Mégie · Senatrice, Senate of Canada
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Stan Kutcher · Senator, Senate of Canada
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Andrew Cardozo · Senator, Senate of Canada
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Carol Hughes · Member of Parliament, House of Commons
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Office of Life Sciences and Biomanufacturing Readiness (OLSBR), Innovation, Science and Economic Development Canada (ISED)
Industry
-
Reported by Najah Sampson · In-house (corporation)
- Stefania Trombetti · Assistant Deputy Minister, Drug Shortages Task Force, Health Canada (HC)
Health
-
Reported by Najah Sampson · In-house (corporation)
- Jean-Yves Duclos · Minister, Public Services and Procurement Canada (PSPC)
Government Procurement
-
Reported by Najah Sampson · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Christopher Johnstone · Assistant Deputy Minister, Health Canada (HC)
HealthIndustryInternational Trade
-
Reported by Najah Sampson · In-house (corporation)
- Tina Green · Assistant Secretary, Treasury Board Of Canada Secretariat (TBS)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Ritu Banerjee · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Celia Lourenco · Acting Associate Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Stefania Trombetti · Assistant Deputy Minister, Health Canada (HC)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Stefania Trombetti · Assistant Deputy Minister, Health Canada (HC)
- Sandenga Yeba · Deputy Director of Policy, Health Canada (HC)
HealthIndustry
-
Reported by Najah Sampson · In-house (corporation)
- Jocelyne Voisin · Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Najah Sampson · In-house (corporation)
- James Fitz-Morris · Director of Communications, Public Services and Procurement Canada (PSPC)
Government Procurement
-
Reported by Najah Sampson · In-house (corporation)
- Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
Government Procurement
-
Reported by Najah Sampson · In-house (corporation)
- James Fitz-Morris · Director of Communications, Public Services and Procurement Canada (PSPC)
Government Procurement
-
Reported by Najah Sampson · In-house (corporation)
- Arianne Reza · Associate Deputy Minister, Public Services and Procurement Canada (PSPC)
Government Procurement
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.